Page 2 - Biocon

USFDA rejects Biocon, Viatris application for Insulin Aspart

The company will respond to the CRL to satisfy the FDA's requests

Biocon Biologics partner Viatris wins favourable order from US court

Biocon Biologics Ltd, said its partner Viatris has won favourable decisions from a US federal court in Sanofi's challenge over unpatentability of device patents for disposable insulin injection pen

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.

Trading strategies for Bandhan Bank & Ambuja Cement by Ajit Mishra

The stock of Bandhan Bank has been underperforming the banking index and is still struggling below the resistance zone of moving averages

Biocon in talks with Mylan to merge biosimilar businesses: Report

Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said

Biocon ties up with Tabuk Pharmaceuticals to sell medicines in Middle East

Biocon said it has inked a pact with Saudi Arabia-based drug firm Tabuk Pharmaceutical Manufacturing Company to commercialise select speciality products in Middle East region

Biotechnology major Biocon gets USFDA approval for generic product

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant

Biocon enters Dow Jones Sustainability Index in Emerging Markets category

Pharma major makes it to the DJSI EM Index with a total sustainability score of 45 as against an industry average of 18

Stocks to Watch: IndiGo, Biocon, Pfizer, IEX, TFCI, SAIL, BHEL, Nalco

Indian Energy Exchange and Apollo Pipes have announced their respective record dates for the issuance of bonus shares for eligible shareholders

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

Biocon starts campaign to treat diabetic children, train healthcare workers

India has one of the largest populations of children and adolescents living with Type 1 diabetes in the world with an estimated 1 million patients in this age group

Serum Alliance will give revenue stream from H2FY23: Biocon Biologics exec

In a Q&A, Shreehas Tambe talks about the road ahead for the firm's biosimilars business and how its alliance with Serum is projected to pan out

Ashok Leyland, Biocon look good on charts for a rebound: Ajit Mishra

The technical analyst from Religare Broking also recommends to accumulate United Spirits. Check out the range below

Biocon net rises 11% in Q2 to Rs 188 cr, revenue up 10% at Rs 1,945 cr

Revenue growth was primarily driven by good performance of its research services and biosimilars business segments

Sensex slips 336pts; Nifty Bank at new high; RIL falls 3%, TaMo DVR up 10%

Stock market LIVE: The broader markets also ended with notable losses as profit-taking continued for the third straight trading session, amid valuation and inflation concerns

Biocon's insulin biosimilar Glargine gets preference in top US formulary

The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in July this year

Stocks to Watch: Asian Paints, Biocon, IDBI, JSW Steel, Lodha, TVS Motors

State-run PSU banks and telecom stocks are likely to be in focus along with a slew of mid- and small-cap companies that shall announce their September earnings today

Pandora Papers: 'Kunal Kashyap has no influence over Biocon-linked trust'

According to a company statement, the Deanstone Trust, which was mentioned as part of a leak of offshore tax haven files called the 'Pandora Papers,' was set up for philanthropic endeavours

Decoded: Of 'Pandora Papers', insider trading and Biocon link

Kiran Mazumdar-Shaw, executive chairperson of Biocon denied any impropriety

Allegro Capital named in Pandora Papers: What was the Sebi order about?

Kunal Kashyap's Sebi order was also linked to Biocon. It was related to a 2018 announcement about Biocon's global collaboration with Sandoz